395 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Novartis Tops Q1 Earnings: Cosentyx, Entresto Boost Sales http://www.zacks.com/stock/news/257769/novartis-tops-q1-earnings-cosentyx-entresto-boost-sales?cid=CS-ZC-FT-257769 Apr 25, 2017 - Novartis AG (NVS) reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10.
Bleak Outlook for Big Drug Makers https://www.wsj.com/articles/bleak-outlook-for-big-drug-makers-1493051153?mod=rss_markets_main Apr 25, 2017 - Without price increases or deals to boost earnings, the pharmaceuticals sector faces a weak earnings season.
3 Healthcare Bargain Stocks You Can Buy Right Now https://www.fool.com/investing/2017/04/24/3-healthcare-bargain-stocks-you-can-buy-right-now.aspx?source=iedfolrf0000001 Apr 24, 2017 - Allergan, Express Scripts, and Vertex stocks look attractive in a generally overpriced market.
Should Gilead Sciences Be Worried About Allergan? https://www.fool.com/investing/2017/04/23/should-gilead-sciences-be-worried-about-allergan.aspx?source=iedfolrf0000001 Apr 23, 2017 - Gilead Sciences might want to pay attention to Allergan's aggressive expansion of its NASH program.
Allergan (AGN) Collaborates with Novartis to Treat NASH http://www.zacks.com/stock/news/256887/allergan-agn-collaborates-with-novartis-to-treat-nash?cid=CS-ZC-FT-256887 Apr 19, 2017 - Allergan plc (AGN) entered into a collaboration with Novartis AG (NVS) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (cvc) and Novartis lead Fxr agonist to treat non-alcoholic steatohepatitis
Did Pharma & Biotech M&As Pick Pace in Q1? http://www.zacks.com/stock/news/256645/did-pharma-biotech-mas-pick-pace-in-q1?cid=CS-ZC-FT-256645 Apr 18, 2017 - Post-election, hopes surged that there would be an increase in M&A activity in the pharma and biotech sector in 2017.
Aerie Reports Positive Data on Ophthalmic Drug Rhopressa http://www.zacks.com/stock/news/256284/aerie-reports-positive-data-on-ophthalmic-drug-rhopressa?cid=CS-ZC-FT-256284 Apr 13, 2017 - Aerie Pharmaceuticals, Inc. (AERI) reported encouraging six-month top-line safety and efficacy results from the phase III trial, ROCKET 4, on lead product candidate Rhopressa.
Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK? http://www.zacks.com/stock/news/254783/pharma-stock-roundup-fda-nod-for-sny-roche-drugs-generic-advair-relief-for-gsk?cid=CS-ZC-FT-254783 Mar 31, 2017 - Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.
Why Equal Weighted Mutual Funds Scoring Over Index Funds http://www.zacks.com/stock/news/254739/why-equal-weighted-mutual-funds-scoring-over-index-funds?cid=CS-ZC-FT-254739 Mar 30, 2017 - Investors interested in maintaining a diversified portfolio might consider investing in equal-weight funds.
Allergan Acne Candidate Meets Endpoints in Phase III Studies http://www.zacks.com/stock/news/254397/allergan-acne-candidate-meets-endpoints-in-phase-iii-studies?cid=CS-ZC-FT-254397 Mar 28, 2017 - Allergan plc (AGN) in collaboration with Paratek Pharmaceuticals, Inc. (PRTK) has announced positive results from two phase III studies on sarecycline

Pages: 1...3031323334353637383940

<<<Page 35>